Drugs Targeting EGFR
- Gilotrif (afatinib) – approved for stage 4 NSCLC patients with a change in EGFR as detected by a biomarker test.
- Iressa (gefitnib) – approved for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test.
-
Lazcluze (lazertinib) – approved for stage 3 or 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by a biomarker test.
- Rybrevant (amivantamab-vmjw) – approved for stage 3 or 4 NSCLC with a change in EGFR called exon 20 insertion as detected by a biomarker test. Rybrevant is also approved in combination with chemotherapy for stage 3 or 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test.
- Tagrisso (osimertinib) – approved for stage 3 and 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test. Tagrisso is also approved for stage 4 NSCLC patients with the EGFR T790M change.
- Tarceva (erlotinib) – approved for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test. Tarceva is also approved in combination with Cyramza (ramucirumab) for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test.
- Vizimpro (dacomitinib) – approved for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test.